Trials / Active Not Recruiting
Active Not RecruitingNCT06143878
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 774 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-77242113 | JNJ-77242113 will be administered orally. |
| DRUG | JNJ-77242113 Matching Placebo | JNJ-77242113 matching placebo will be administered orally. |
| DRUG | Deucravacitinib | Deucravacitinib will be administered orally. |
| DRUG | Deucravacitinib Matching Placebo | Deucravacitinib matching placebo will be administered orally. |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2024-09-17
- Completion
- 2027-06-01
- First posted
- 2023-11-22
- Last updated
- 2026-03-12
Locations
164 sites across 13 countries: United States, Argentina, Australia, Brazil, Canada, Germany, Hungary, Japan, Poland, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06143878. Inclusion in this directory is not an endorsement.